Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Early Stage Breast Cancer
Interventions: Paclitaxel, Neulasta; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts + 1 more

Conditions: Glaucoma, Intraocular Pressure, Anesthesia
Interventions: Tono-pen XL Applanation tonometer + Ocu-film +; Drug
Lead sponsor: University of Miami; Other
Eligibility: 1 Year to 18 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Breast Cancer, HER2-negative Breast Cancer
Interventions: Paclitaxel, Eribulin, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 18
States / cities: Denver, Colorado • Miami Beach, Florida • Albany, Georgia + 13 more

Conditions: Healthy Elder People
Interventions: Feru-guard, Placebo; Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 65 Years to 89 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Myeloma
Interventions: carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome, Trisomy 13, Trisomy 18, Sex Chromosome Abnormalities
Interventions: Not listed
Lead sponsor: BillionToOne Inc.; Industry
Eligibility: Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Riverside, California • West Covina, California + 5 more

Conditions: Asthma, Obesity, Family, Child
Interventions: CHAMP, Health education; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 6 Years to 12 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: End Stage Liver Disease
Interventions: Advance Care Planning Video Decision Support Tool, Verbal Narrative; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Surgery
Interventions: ECG; Device
Lead sponsor: Senthil G. Krishna; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Glioblastoma Multiforme, Adult
Interventions: Berubicin, Lomustine; Drug
Lead sponsor: CNS Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 32
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more

Conditions: Her2-Positive Breast Cancer
Interventions: Pertuzumab, Trastuzumab, Paclitaxel, 5-fluorouracil, Epirubicin, Cyclophosphamide; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: CS5001, Rituximab, Gemcitabine, Oxaliplatin, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug · Biological
Lead sponsor: CStone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: East Setauket, New York • New York, New York • Dallas, Texas

Conditions: Hiv
Interventions: Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • San Antonio, Texas + 1 more

Conditions: Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions: Prolonged Exposure Therapy, Attendance-based monetary incentives; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
Interventions: BMX-001, Paclitaxel (Taxol); Drug
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, vinorelbine ditartrate; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Child Obesity
Interventions: FUNPALs Playgroup, Healthy Toddler Parent Group; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression
Interventions: Cognitive Therapy, Medications; Behavioral · Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Atrial Fibrillation
Interventions: General Anesthesia with endotracheal tube, General Anesthesia with laryngeal mask airway; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Stroke, Post-stroke Depression
Interventions: Physical capacity training for chronic stroke - building aerobic capacity and muscle strength; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity
Interventions: Parents and Tots Together Program, Control; Behavioral
Lead sponsor: University of Guelph; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Orthopedic/Podiatry Procedures
Interventions: Dexmedetomidine Hcl infusion, normal saline; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Cancer, Small Cell Lung Cancer
Interventions: Ganetespib, Doxorubicin; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Methemoglobinemia
Interventions: 4% prilocaine plain, 2% Lidocaine with 1:100,000 epinephrine; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Loma Linda, California

Search by objective public record fields.

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Feru-guard and General Antioxidant Capacity in Older People

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment

The Childhood Health and Asthma Management Program

A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease

Effect of Dexmedetomidine on QT Interval in Pediatric Patients Under General Anesthesia

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Third Ward Wellness Study for Families

Prevention of Recurrence in Depression With Drugs and CT

General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation

Physical Capacity Building for Chronic Stroke

Parents and Tots Together: A Family-Based Obesity Prevention Intervention

Effects of Dexmedetomidine on Tourniquet Pain Associated With Lower Extremity Surgeries Under General Anesthesia

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics